Spero Therapeutics, Inc.
Div Spero
CAGE Code: 7SK81
NCAGE Code: 7SK81
Status: Active
Type: Commercial Supplier
Summary
Spero Therapeutics, Inc., Div Spero is an Active Commercial Supplier with the Cage Code 7SK81.
Address
14Th Floor
675, Massachusetts Avenue
Cambridge MA 02139-3309
United States
Points of Contact
No Points of Contact...
Related Information
No Related Information...
People who viewed this 'CAGE Code' also viewed...
Course Technology Inc Air/Liquid America Specialty Building Services Avery And Saul Co Inc Moldyn Inc Advanced Position Systems Inc. Bbn Planet Corp Northeast Scientific Corp Forrester Research Inc Ruffcorn Fastener Co Quantum Energy Technologies Corp International Integration Voltaris, Llc Heritage Resource Group, Inc. National Bureau Of Economic Research Cellxicus, Inc. Pegasus Communiations Inc Altus Pharmaceuticals Inc. Polaroid Express Minnesota State Colleges &
Frequently Asked Questions (FAQ) for CAGE 7SK81
- What is CAGE Code 7SK81?
- 7SK81 is the unique identifier used by NATO Organizations to reference the physical entity known as Spero Therapeutics, Inc. Div Spero located at 14Th Floor, 675, Massachusetts Avenue, Cambridge MA 02139-3309, United States.
- Who is CAGE Code 7SK81?
- 7SK81 refers to Spero Therapeutics, Inc. Div Spero located at 14Th Floor, 675, Massachusetts Avenue, Cambridge MA 02139-3309, United States.
- Where is CAGE Code 7SK81 Located?
- CAGE Code 7SK81 is located in Cambridge, MA, USA.
Contracting History for CAGE 7SK81 Most Recent 25 Records
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 27 Jun 2023
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,212,184.27
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- Eo14042 - To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 14 Oct 2021
- Eo14042 - To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,089,779.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 26 Oct 2022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,062,702.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 11 Dec 2023
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,076,984.27
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 8 Aug 2023
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,991,776.27
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 23 Feb 2023
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $6,212,184.27
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 11 May 2022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $2,089,779.00
- Department Of Health And Human Services (Hhs)
- 75N93021C00022
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- 23 Aug 2023
- To Advance Clinical And Non-Clinical Development Of An Antibiotic Candidate.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $7,076,984.27
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Exercise Of Option 1 (Clin 0002)
- 31 Jan 2020
- Exercise Of Option 1 (Clin 0002)
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- This Mod Should Include Updated Sow, Go/No-Go Milestones, Gantt Chart) Change The Co From Kathy To Jonathan Gonzalez; Change Key Personnel Cmo From David To Kamal; Reflect Changes To Ipp System For Invoicing.
- 28 Sep 2022
- This Mod Should Include Updated Sow, Go/No-Go Milestones, Gantt Chart) Change The Co From Kathy To Jonathan Gonzalez; Change Key Personnel Cmo From David To Kamal; Reflect Changes To Ipp System For Invoicing.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Change Cor
- 21 Sep 2022
- Change Cor
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Igf::Ot::Igf
- 19 May 2019
- Igf::Ot::Igf
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- HHSN272201500014C
- Development Of A Second Generation Polymyxin For Therapy Of Mdr Gram-Negative Infections
- 8 Apr 2022
- Development Of A Second Generation Polymyxin For Therapy Of Mdr Gram-Negative Infections
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $5,923,718.98
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Exercise Of Option 1 (Clin 0002)
- 3 Nov 2020
- Exercise Of Option 1 (Clin 0002)
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Change Cor
- 11 Feb 2022
- Change Cor
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Provide A Nce Through 12/15/2022; Incorporate Covid-19 Language; Update Sow
- 27 Oct 2021
- Provide A Nce Through 12/15/2022; Incorporate Covid-19 Language; Update Sow
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- This No Cost Bilateral Modification To Amend The Key Personnel Section Within The Contract. Dr. Akash Jain Will Replace Erin Wenzel As Director Alliance Management. All Other Terms And Conditions Remain Unchanged. 2. Add Far Clause 52.204-27 Prohibit
- 11 Jul 2023
- This No Cost Bilateral Modification To Amend The Key Personnel Section Within The Contract. Dr. Akash Jain Will Replace Erin Wenzel As Director Alliance Management. All Other Terms And Conditions Remain Unchanged. 2. Add Far Clause 52.204-27 Prohibit
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- This No Cost Bilateral Modification Is For A No Cost Extension For Clin 0002.
- 20 Oct 2023
- This No Cost Bilateral Modification Is For A No Cost Extension For Clin 0002.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- This Mod Is To Revise Sow For Clin 2 To Reflect The New Development Plan For Tebipenenem Hbr Following Fda Feedback At The Type A Meeting, As Well As The Complete Response Letter Received In June 2022.
- 25 Oct 2022
- This Mod Is To Revise Sow For Clin 2 To Reflect The New Development Plan For Tebipenenem Hbr Following Fda Feedback At The Type A Meeting, As Well As The Complete Response Letter Received In June 2022.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Change Key Personnel And Update Related Article
- 27 May 2021
- Change Key Personnel And Update Related Article
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Advance The Development Of Spr994 As An Oral Therapy For Use In Adults To Treat Complicated Urinary Tract Infections (Cutis), Including Those Caused By Drug Resistant Bacteria
- 20 Dec 2023
- Advance The Development Of Spr994 As An Oral Therapy For Use In Adults To Treat Complicated Urinary Tract Infections (Cutis), Including Those Caused By Drug Resistant Bacteria
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,675,699.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Exercise Option 3/Clin0004
- 14 Jan 2022
- Exercise Option 3/Clin0004
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)
- 75A50118C00015
- Igf::Ot::Igf
- 12 Jul 2018
- Igf::Ot::Igf
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $31,034,069.00
- Department Of Health And Human Services (Hhs)